EMEA-002886-PIP01-20-M03 - paediatric investigation plan

rocatinlimab

Key facts

• Active substance:
  rocatinlimab
• Therapeutic area:
  Dermatology
• Decision number:
  P/0264/2023
• PIP number:
  EMEA-002886-PIP01-20-M03
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of atopic dermatitis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  14/07/2023
• Compliance check done:
  No

Decision

P/0264/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for rocatinlimab (EMEA- 002886-PIP01-20-M03)

Reference Number: EMA/285643/2023